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In ovarian cancer, loss ofBRCAgeneexpression in tumors is associatedwith improved response to chemotherapy and
increased survival. A means to pharmacologically downregulate BRCA gene expression could improve the outcomes
of patients with BRCA wild-type tumors. We report that vascular endothelial growth factor receptor 3 (VEGFR3)
inhibition in ovarian cancer cells is associated with decreased levels of both BRCA1 and BRCA2. Inhibition of VEGFR3
in ovarian tumor cells was associated with growth arrest. CD133+ ovarian cancer stemlike cells were preferentially
susceptible to VEGFR3-mediated growth inhibition. VEGFR3 inhibition–mediated down-regulation of BRCA gene
expression reversed chemotherapy resistance and restored chemosensitivity in resistant cell lines in which a BRCA2
mutation had reverted to wild type. Finally, we demonstrate that tumor-associatedmacrophages are a primary source
of VEGF-C in the tumor microenvironment. Our studies suggest that VEGFR3 inhibition may be a pharmacologic
means to downregulate BRCA genes and improve the outcomes of patients with BRCA wild-type tumors.
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Loss ofBRCA gene expression is a double-edged sword. BRCAmutation
carriers have a 40% to 80% lifetime risk of breast cancer and a 20% to
40% lifetime risk of ovarian cancer [1]. However, BRCA mutation
carriers who develop breast or ovarian cancer have a better prognosis than
non-BRCA mutation carriers; BRCA+ patients with ovarian cancer will
have a nearly 30% improvement in overall survival, whereas BRCA+
patients with breast cancer will have a nearly 10% improvement in
overall survival [2,3]. This improved outcome is presumed to be due to
an increase in chemosensitivity to DNA-damaging chemotherapies such
as cisplatin. When BRCA+ patients develop chemotherapy-resistant
disease, nearly 50% will have had a BRCA gene reversion [4]. Once a
patient with ovarian cancer develops platinum-resistant disease, it is
essentially universally fatal, with a 5-year survival of less than 10%.
In addition to genetic changes in tumor cells, host cells can
contribute to chemotherapy resistance. Tumor-associated macro-
phages (TAMs) have been reported to have many roles in the tumormicroenvironment. In addition to promoting angiogenesis and
suppressing antitumor immunity, recent studies suggest that TAMs
can promote chemotherapy resistance [5]. TAMs secrete numerous
angiogenic factors including both vascular endothelial growth factor A
(VEGF-A) and VEGF-C [6–10]. VEGF-A has a well-documented
role in tumor angiogenesis, whereas VEGF-C has a primary role in
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directly impact cancer cells including cancer stemlike cells (CSCs).
Vascular endothelial growth factor receptor 2 (VEGFR2), the primary
receptor for VEGF-A, is preferentially expressed on glioma stem cells
and promotes stem cell viability and growth, tumor cell migration,
and vascular mimicry [11,12]. In breast cancer and glioma stem cells,
treatment with anti–VEGF-A antibodies is associated with increased
tumor hypoxia, resulting in the induction of hypoxia inducible factor
proteins and increased stemness [13,14].
Less is known about the role of VEGF-C and VEGF-D in relation
to their impact on cancer cells. VEGF-C levels are correlated with
patient prognosis [15–21] and down-regulation of VEGF-C results
in reduced lung and colon cancer metastases in mice [22]. Similarly,
inhibition of VEGFR3 (primary receptor for VEGF-C/VEGF-D) is
associated with reduced growth and metastasis in breast and
pancreatic tumor models [23–25]. In specimens of patients with lung
cancer, the level of expression of the CSCmarker nestin correlated with
lymphangiogenesis and nodal metastasis [26]. Most recently, soluble
VEGFR3, used as a means to inhibit VEGF-C/VEGF-D, was found to
reduce carcinogenesis in a murine model of skin carcinogenesis,
suggesting a role for VEGF-C/VEGF-D in early tumor events [27].
One source of VEGF-C in the tumor microenvironment is a
population of tumor-associated myeloid cells [28]. In ovarian cancer, we
previously reported on an abundant population of tumor-associated
myeloid cells termed vascular leukocytes (VLCs) [29,30]. Here, we report
that VLCs produce high levels of VEGF-C, whereas tumor cells express
VEGFR3 (little VEGF-D was detected in ovarian tumors). We
demonstrate that VEGFR3 inhibition leads to preferential cell cycle arrest
of CD133+ ovarian CSCs. Cell cycle arrest is associated with decreased p-
extracellular signal-regulated kinase (p-ERK), E2F1, and bothBRCA1 and
BRCA2 expression. Furthermore, VEGFR3 inhibition and its resultant
decreased expression of BRCA1 and BRCA2 were associated with
significant increased chemosensitivity both in vitro and in vivo. This
strongly supports VEGFR3 as a therapeutic target in ovarian cancer.
Materials and Methods
Tumor Cells and Cytotoxic Assays
Informed consent was obtained from patients for tissue
procurement in accordance with the protocol approved by the
University of Michigan’s Institutional Review Board. All tumors
obtained were stage III or IV epithelial ovarian, fallopian tube, or
primary peritoneal cancer of serous histology. Fresh tumor
specimens were minced and processed into single-cell suspensions,
and red cells were lysed as previously described [31]. For ovarian
cancer ascites samples, cells were isolated through centrifugation,
and red cells were lysed using ammonium-chloride-potassium
(ACK) buffer (Lonza Walkersville Inc., Walkersville, MD). A2780
(wild-type p53, BRCA1, BRCA2), OVCAR8 (p53 null, wild-type
BRCA1, BRCA2) [32], PEO1 (p53 mutant, BRCA1 wild type,
BRCA2 null, p16 deleted), and PEO4 (p53 mutant, BRCA1 wild
type, BRCA2 revertant to wild type, p16 deleted) [33,34] ovarian
cancer cell lines were obtained from Susan Murphy (Duke
University, Durham, NC). Isogenic murine cancer cell lines with
and without BRCA1 deletion were a generous gift of Sandra
Orsulic (Cedars-Sinai Cancer Center, Los Angeles, CA). Cell lines
were cultured in RPMI-10 (10% fetal bovine and 1% streptomy-
cin/penicillin; Invitrogen, Carlsbad, CA) for 24 hours and then
treated with indicated doses of the VEGFR3 tyrosine kinaseinhibitor Maz51 (Calbiochem, San Diego, CA,) daily for 3 days.
Cell numbers and viability were then evaluated using the Cell
Countess (Invitrogen). For chemosensitization assays, cells were
treated with 5 μM Maz51 and 0.5 μg/ml cisplatin in the indicated
sequence. For drug sequencing, A2780 or OVCAR8 cell replicates
were treated with 1) DMSO (control), 2) Maz51 (5 μM) daily for
3 days, 3) 0.5 μg cisplatin for 3 days, 4) Maz51 for 3 days followed
by cisplatin for 3 days, 5) cisplatin for 3 days followed by Maz51 for
3 days, or 6) cisplatin and Maz51 concurrent for 3 days. Each assay
was repeated at least three times.
Fluorescence-Activated Cell Sorting
Cells from human ovarian cancer cell lines (A2780 and OVCAR8),
human ascites, or primary ovarian tumors were processed and prepared as
previously reported [35]. Cells were incubated with monoclonal anti-
humanVEGFR3-PE (R&DSystems,Minneapolis,MN) andCD133/2
(Allophycocyanin [APC]-tagged; Miltenyi Biotec, Gladbach, Germany)
or for isotype control with Mouse IgG2A APC and Mouse IgG2A
phycoerythrin (PE) (R&D Systems) and then ALDEFLUOR (Stemcell
Technologies, Vancouver, Canada) as previously described [36]. Results
were analyzed using Summit 6.0 (Beckman-Coulter, La Brea, CA).
Tumor Sphere Assays
Five thousand cells in 3 ml of supplemented MEBM (Lonza) were
plated onto each well of six-well ultralow adherence plates (Corning,
Acton,MA). After 24 hours, cells were treated withmedia alone (control)
orMaz51 in media, at 1, 2.5, or 5 μMconcentrations. After 3 days, fresh
media were addedwithoutMaz51.Media were changed every 3 to 4 days,
and tumor spheres were counted after 2 weeks. Images of spheres were
photographed and quantified using the Olympus MicroSuite Biological
Suite software (Center Valley, PA), as previously described [37].
Western Blot Analysis
A2780 and OVCAR8 ovarian cancer cells were grown to 80%
confluence. To detect VEGF-C, protein transport inhibitor GolgiPlug
(BDBiosciences, San Jose, CA) was added tomedia (1μl/ml) for 4 hours,
and then cells were lysed with Radioimmunoprecipitation assay buffer
(RIPA buffer) (Invitrogen) with complete proteinase inhibitor and
phosphatase inhibitor (Roche, Basel, Switzerland). Insoluble material was
removed by centrifugation at 16,000g at 4°C for 15 minutes. Protein
concentrations were determined using the Bradford Protein Assay Kit
(Bio-Rad Laboratories, Hercules, CA). To detect phosphoproteins after
treatment with VEGF-C (PeproTech, Rocky Hill, NJ), A2780 and
OVCAR8 cells were grown to 60% confluence, serum starved for
16 hours, and then treated with 50 ng/ml VEGF-C for 30minutes. Cells
were washed with ice-cold phosphate-buffered saline (PBS) and then
lysed and processed as above. Standard Western blot analysis was
performed with 10 μg of total protein per sample. Antibodies used for
Western blot analysis include anti–VEGF-C (1:800 dilution; Santa Cruz
Biotechnology, Santa Cruz, CA), anti-VEGFR3 (1:1000 dilution;
Chemicon, Temecula, CA), anti–p-VEGFR3 (1:1000 dilution; Calbio-
chem, Madison, WI), anti–p-ERK 1/2 and anti-ERK (1:1000 dilution;
Cell Signaling Technology, Danvers, MA), and anti–β-actin (1:10,000
dilution; Sigma-Aldrich, Saint Louis, MO). Bands were visualized using
the ECL Kit (Pierce/Thermo Scientific, Rockford, IL), anti–p-p38 and
anti-p38 (1:1000 dilution; Cell Signaling Technology), anti–p-jnk and
anti-jnk (1:1000 dilution; Cell Signaling Technology), anti–p-AKT and
anti-AKT (1:1000 dilution; Cell Signaling Technology), and anti–p-stat3
and anti-stat3 (1:1000 dilution; Cell Signaling Technology).
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A population of 5 × 104 A2780 or OVCAR8 cells was fixed in
70% cold ethanol. After washing with cold PBS, the cells were
stained with PBS containing 50 μg/ml propidium iodide (Sigma-
Aldrich) and treated with 100 μg/ml RNase A for 30 minutes at
room temperature. Cells were analyzed using a FACSCalibur
flow cytometer (Becton Dickinson, Franklin Lakes, NJ).
Apoptosis was characterized using the PI/annexin V FITC kit
(BD Biosciences) as previously described [38]. The cell apoptosis
distributions were determined on a FACSCalibur flow cytometer
(BD Biosciences) and analyzed by CellQuest Pro software
program (Becton, Dickinson and Company, Franklin Lakes, NJ).
Bromodeoxyuridine Proliferation Assays
For bromodeoxyuridine (BrdU) labeling, 0.1 × 105 A2780 cells
and 0.5 × 105 OVCAR8 cells were plated onto an eight-well chamber
slide (Lab-Tek, Scotts Valley, CA) in RPMI-10 (10% fetal bovine and
1% streptomycin/penicillin; Invitrogen) and incubated in 37°C 5%
CO2/air mixture for 24 hours. Cells were treated with plain media
(control) or Maz51 (5 μM) daily for 3 days, then incubated with
10 μM BrdU (Sigma-Aldrich) for 2 hours, and then 10% formalin
fixed. BrdU incorporation was assessed through immunofluorescence.
Sixteen high-power images (×100) from each treatment group were
compared versus control using the two-sided Student’s t test.
Quantitative Real-Time Reverse Transcription–Polymerase
Chain Reaction
Cells were treated with plain media + DMSO (control) or 5 μM
Maz51 or U0126 for 24 hours; then, total RNAwas extracted from cells
with the PureLink Total RNA Purification System (Invitrogen) with
on-column DNAse treatment. RNA quality was confirmed on 2100
Bioanalyzer (Agilent Technologies, Santa Clara, CA). First-strand
cDNAwas synthesized from 2 μg of total RNAwith the SuperScript III
First-Strand Synthesis System for reverse transcription–polymerase
chain reaction (RT-PCR) (Invitrogen) according to manufacturer
recommendations. SYBRGreen–based array PCRwas performed using
the 7900 HT Sequence Detection System (Applied Biosystems, Grand
Island, NY) and the indicated primer (Table W1).
Animal Studies
Six- to eight-week-old nude NOD-SCIDmice were purchased from
Charles River Laboratories (Wilmington, MA). All experiments were
performed with approval of the University of Michigan Committee on
Use and Care of Animals. Tumors were initiated with 5 × 105 A2780 or
1 × 107 OVCAR8 cells combined with 100 μl of phosphate buffered
saline (PBS) and 100 μl of Matrigel (BD Biosciences), implanted
subcutaneously into the axillae (n = 10 tumors per treatment group).
Three days after tumor inoculation, mice were treated through
intraperitoneal injection with 1) control DMSO (40 μl) or 2) Maz51
(8 mg/kg in 40 μl of DMSO). Tumor growth was measured using
calipers, and tumor volume was calculated on the basis of the following
modified ellipsoid formula: (L × W × W)/2.
Immunohistochemistry
Aportion of each tumorwas fixed in 10% formalin for 2 hours at room
temperature and then transferred to 70% ethanol. Tumors were then
paraffin embedded and stained at the histology core of the University of
Michigan using EDTA-based antigen retrieval and either mouse anti-
aldehyde dehydrogenase (anti-ALDH) antibody (clone 44/ALDH;1:100; BD Biosciences) or anti-Ki67 antibody (Abcam, Cambridge,
UK; No. 15580, 1:2000). For stain quantification, 8 to 10 sections from
four to five tumors per treatment group were analyzed, and counts were
compared using the two-sided Student’s t test.
Results
Expression of VEGF-C, VEGF-D, and VEGFR3 in
Ovarian Cancer
We evaluated the expression of VEGF-C, VEGF-D, and their primary
receptor, VEGFR3, in primary tumor endothelial cells (TECs), VLCs,
and ovarian cancer cells. Quantitative real-time RT-PCR (qRT-
PCR) evaluation of VEGF-C expression demonstrated 5 to 10×
higher expression in VLCs compared to TECs and tumor cells
(Figure 1A). Western blot confirmed the highest levels of VEGF-C
protein in VLCs (Figure 1C). In contrast, qRT-PCR demonstrated
the greatest expression of VEGFR3 in tumor cells (Figure 1B). FACS
and immunocytochemistry of both A2780 and OVCAR8 ovarian
cancer cell lines confirmed VEGFR3 protein expression (Figure 1D
and data not shown). Immunohistochemistry performed on primary
human tumors confirmed expression of VEGFR3 in tumor cells and
vascular cells (Figure 1E). In normal ovary, VEGFR3 expression was
found primarily in vessels and in some stromal cells, with no
expression appreciated on ovarian surface epithelial cells. Treatment
of both A2780 and OVCAR8 cell lines with VEGF-C resulted in
phosphorylation of VEGFR3, indicating that VEGF-C signaling is
active in ovarian cancer cells (Figure 1F).
VEGFR3 Inhibition Results in Tumor Cell Growth Arrest
We next tested the impact of the VEGFR3 inhibitor Maz51 on
OVCAR8 and A2780 cell growth. OVCAR8 demonstrated a dose-
dependent reduction in cell growth, with an IC50 of approximately
2.5 μM, and nearly complete growth arrest at 5 μM (Figure 2A).
A2780 demonstrated a biphasic response, with a slight increase in
growth at 1 μMMaz51, modest growth suppression at 2.5 μM, and
nearly complete growth arrest at 5 μM (Figure 2A). Cell cycle
analysis with Maz51 demonstrated a significant decrease in the
number of cells in S/M phase, with a concurrent increase in the
number of cells in G0/G1 (Figure 2B). Treatment was not associated
with an increase in the number of sub-G0/apoptotic cells. In
addition, annexin/PI analysis did not demonstrate apoptosis (Figure
W1). Treatment with the VEGFR2 inhibitor Sutent (Pfizer, New
York, NY) was not associated with cell cycle arrest (data not shown),
suggesting that the impact of Maz51 was not due to cross-reactivity
with the VEGFR2. To further confirm that the impact of VEGFR3
inhibition on tumor cell growth was due to cell cycle arrest, we
evaluated BrdU incorporation into both cell lines in the presence and
absence of VEGFR3 inhibition. As anticipated, VEGFR3 inhibition
was associated with an about two to three times reduction in BrdU
incorporation (Figure 2C). Similarly, we evaluated Carboxyfluores-
cein succinimidyl ester (CFSE) dilution. Cells treated with Maz51
demonstrated slower CFSE dilution compared to untreated controls
(data not shown). Taken together, these data indicate that Maz51
induces growth arrest, but not death, of ovarian cancer cells.
VEGFR3 Inhibition Preferentially Impacts CD133+ Cells
VEGFR3 inhibition consistently had greater impact on OVCAR8
cells versus A2780 cells. More than 90% of OVCAR8 cells express the
CSC marker CD133, whereas ~5% to 10% of A2780 cells express
Figure 1. Expression of VEGF-C, VEGF-D, and VEGFR3 in ovarian cancer. (A and B) qRT-PCR evaluation of VEGF-C mRNA and VEGFR3
mRNA in VLCs, TECs, and primary ovarian tumor cells (TCs) is presented. (C) Western blot confirms high VEGF-C protein expression in
VLCs. (D) FACS analysis of VEGFR3 and CD133 in A2780 and OVCAR8 cells is presented. (E) Immunohistochemistry demonstrating
VEGFR3 expression in human ovary is primarily in vessels and rare stromal cells, whereas VEGFR3 expression in primary ovarian tumors is
in vascular structures and tumor cells (original magnification, ×100). (F) p-VEGFR3Western blot of A2780 tumor cells treated with VEGF-C
is shown.
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Figure 2. VEGFR3 inhibition results in ovarian cancer cell growth arrest and preferentially targets CD133+ cells. (A) OVCAR8 and A2780
tumor cell number (relative to untreated controls) after treatment with the indicated doses of Maz51 is presented. (B) Propidium iodide
FACS cell cycle analysis of control and Maz51-treated OVCAR8 and A2780 cells is presented. (C) Quantification of BrdU incorporation in
control andMaz5-treated OVCAR8 and A2780 cells is presented. (D) Total cell numbers (normalized to untreated control) of FACS-isolated
CD133+ versus CD133−OVCAR8 and A2780 cells after treatment with the indicated doses ofMaz51 are presented. (E) Quantification and
representative images of tumor spheres formed from three independent primary ovarian cancer cell specimens in the absence and
presence of increasing doses of Maz51 are shown.
Neoplasia Vol. 16, No. 4, 2014 VEGFR3 Regulates BRCA1 and BRCA2 Expression Lim et al. 347
348 VEGFR3 Regulates BRCA1 and BRCA2 Expression Lim et al. Neoplasia Vol. 16, No. 4, 2014CD133+ [35,39]. We therefore evaluated the impact of VEGFR3
inhibition specifically on CD133+ ovarian tumor cells. Treatment of
A2780 cells with increasing doses of Maz51 was associated with
decreasing percentages of CD133+ cells (data not shown). To directly
test the impact of Maz51 on CD133+ cells, we treated FACS-isolated
CD133+ and CD133− cells from OVCAR8 and A2780. In both cell
lines, CD133+ cells were sensitive to lower doses of Maz51 (Figure 2D).
To confirm a potential impact on primary human ovarian CSC
growth, we performed tumor sphere assays on tumor cells directly
isolated from patients with ovarian cancer in the presence and absence
of Maz51. Similar to that seen with cell line data, low doses (1 μM) of
Maz51 were associated with slight increases in tumor sphere number,
whereas 5 μM doses of Maz51 were associated with nearly complete
inhibition of tumor sphere formation (Figure 2E).
Impact of VEGFR3 Inhibition on Cell Signaling
We next evaluated downstream targets of VEGFR3 activation.
Phosphoprotein Western blot analysis in both A2780 and OVCAR8
cells demonstrated that VEGF-C treatment of cells was associated with
increased p-ERK levels that could be blocked by Maz51 treatment
(Figure 3A, i). In the more sensitive OVCAR8 cells, VEGFR3 inhibition
was also associated with decreased levels of p-JNK and p38 (Figure 3A, i).
Given that VEGFR3 inhibition was associated with cell cycle arrest
and thatBRCA genes are known to regulate cell cycle, we next specifically
evaluated the impact of VEGFR3 inhibition on BRCA1 and BRCA2
expression. In both cancer cell lines (A2780 andOVCAR8) and primary
cells, we observed that VEGFR3 inhibition was associated with
approximately three- to nine-fold down-regulation of BRCA1 and
BRCA2 mRNA (Figure 3B). Western blot analysis confirmed that
Maz51 treatment of A2780 and OVCAR8 cells decreased expression of
BRCA1 protein (Figure 3A, ii). With Maz51 treatment, we also
observed decreased levels of E2F1 in both cell lines, increased levels of
p53 in A2780 (OVCAR8 cells are p53 null), and increased levels of
cyclin-dependent kinase inhibitor 1B/p27) in OVCAR8 (Figure 3A, ii).
To determine if phosphorylation of ERK plays a central role in
VEGFR3 inhibition–mediated inhibition of BRCA gene expression,
we treated A2780, OVCAR8, and primary ovarian tumor cells with
the mitogen-activated protein kinase kinase 1 (MEK) inhibitor
U0126 and assessed BRCA1 and BRCA2 mRNA levels. MEK
inhibition reduced both BRCA1 and BRCA2 mRNA levels albeit
somewhat less effectively than Maz51 (Figure 3B, ii).
To confirm an important role of BRCA gene down-regulation
important role in Maz51 mediated growth arrest, we treated murine
ovarian tumor cell lines with and without BRCA1 mutation. Murine
tumor cells with wild-type BRCA1 are more sensitive to Maz51
treatment than are syngeneic cell lines withmutant BRCA1 (Figure 3C,
i). We also tested human PEO1 ovarian cancer cells (BRCA2 deficient
due to a nonsense mutation) and PEO4 ovarian cancer cells (BRCA2
revertant cells derived from the same patient as PEO1 cells) [40].
BRCA2-deficient chemotherapy-sensitive PEO1 cells were less respon-
sive to Maz51 therapy, whereas BRCA2 wild-type chemotherapy-
resistant PEO4 cells were more responsive to Maz51 (Figure 3C, ii).
VEGFR3 Inhibition Induces Chemosensitization In Vitro and
In Vivo
Loss of BRCA function in patients is associated with increased
chemosensitivity and significantly improved outcome in ovarian cancer.
We therefore tested the impact of Maz51 on chemotherapy response of
ovarian cancer cell lines. We treated OVCAR8 and A2780 cell lines withMaz51 before, concurrent with, or after cisplatin chemotherapy.
Pretreatment with Maz51 followed by chemotherapy was the most
effective means to delay tumor regrowth (Figure 4A). We also assessed
chemotherapy sensitivity in PEO1 and PEO4 cells. BRCA2-null PEO1
cells are sensitive to cisplatin, whereas BRCA2-revertant PEO4 cells are
resistant to cisplatin. However, chemotherapy resistance in PEO4 was
reversed in the presence of Maz51 (Figure 4B).
We next tested the impact of Maz51 treatment on A2780 and
OVCAR8 tumor growth in vivo. Single-agent Maz51 treatment
demonstrated profound growth inhibitory effects on the OVCAR8
tumor cell line, which is N90% CD133+ (Figure 5A). However, A2780
tumors, which have a small percentage of CD133+ cells (~5%-10%),
demonstrated no response to single-agent Maz51 therapy (Figure 5A).
We next tested the impact of Maz51 in combination with cisplatin
chemotherapy in A2780 cells. Given our in vitro sequencing studies, we
initiated Maz51 treatment before weekly chemotherapy treatment with
cisplatin. Maz51 treatment was followed with low-dose chemotherapy
that resulted in a significant reduction inA2780 tumor growth (Figure 5B,
i) compared to cisplatin therapy alone. Evaluation of Maz51-treated
tumors demonstrated significant reductions in Ki67 and reduced levels of
LYVE1+ vessels (Figure 5B, ii, and data not shown). No differences were
observed in CD31+ vessels, indicating no effects from VEGFR2
inhibition (data not shown). FACS analysis of tumors at the time of
killing demonstrated a higher percentage (Figure 5C, i), but modest
decreased absolute number of CD133+ cells in Maz51 + cisplatin versus
cisplatin only–treated tumors (Figure 5C, ii). CD133− cells demonstrated
~10-fold decrease in absolute number with combined Maz51 + cisplatin
treatment versus cisplatin treatment alone (Figure 5C).Discussion
Our studies indicate a critical role for VEGF-C regulation of ovarian
cancer cell gene expression. VEGF-C blockade results in down-
regulation of both BRCA1 and BRCA2, leading to chemosensitization.
The primary source of VEGF-C in the tumor microenvironment is
tumor-associated myeloid cells.
These studies indicate another critical role formyeloid cells in the tumor
microenvironment. Populations of tumor-associatedmyeloid cells, defined
by the expression of various molecules (CD14, CD11b, GR, Tie2, and
F4/80), have been reported to promote angiogenesis and suppress
antitumor immunity [41]. In addition,myeloid cells have been linkedwith
increased rates of tumormetastasis and establishment of a metastatic niche
[42–44]. More recently, myeloid cells have been reported to directly
impact cancer stemlike cells [45,46]. Our findings that ovarian cancer–
associatedmyeloid cells produce high levels ofVEGF-C are consistentwith
previous reports that CD14+CD11b+ cells produce high levels of VEGF-
C to produce robust but aberrant lymphangiogenesis [28]. Our studies
indicate that VEGF-C, in addition to its well-known effects on
lymphangiogenesis, has direct effects on the cancer cell.
We found that inhibition of VEGFR3 in both ovarian cancer cell
lines (OVCAR8 and A2780) and primary tumor cells dramatically
restricted tumor cell growth. CD133+ ovarian cancer stemlike cells
were preferentially sensitive to VEGFR3 inhibition. At a dose of 5 μM,
we found essentially 100% growth inhibition. In all cells tested,
Maz51 treatment–associated growth restriction was linked to reduc-
tions in p-ERK, E2F, and BRCA gene expression. Treatment with a
MEK inhibitor partially reducedBRCA gene expression, suggesting that
signaling fromVEGFR3 through p-ERK regulates transcription factors,
such as E2F, which at least partly contribute to the regulation of BRCA
Figure 3. VEGFR3 inhibition decreases BRCA1 and BRCA2 gene expression through p-ERK and E2F1. (A) (i) Phosphoprotein Western blot
analysis of control and VEGF-C–treated A2780 and OVCAR8 cells in the presence or absence of Maz51 showing VEGF-C treatment is
associated with increased p-ERK. (ii) Western blot demonstrating Maz51 treatment is associated with decreased BRCA1 and E2F1 in both
A2780 and OVCAR8 cells. (B) qRT-PCR demonstrating treatment with (i) Maz51 or (ii) MEK inhibition is associated with down-regulation of
BRCA1 and BRCA2 mRNA. (C). Comparison of cell growth inhibition of Maz51 in (i) two sets of isogenic control and BRCA1 knockout
murine ovarian cancer cell lines and in (i) BRCA2 mutant PEO1 and BRCA2 revertant PEO4 cells.
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with mutant BRCA1 or BRCA2 genes were two- to three-fold more
resistant to VEGFR3 inhibitor therapy. In A2780 cells, growth
reduction could also potentially be associated with stabilization of p53.
InOVCAR8 cells, which do not express a functional p53 null, increased
p27 could also account for some growth arrest.
With VEGFR3 inhibitor therapy, we observed increased chemo-
sensitivity both in vitro and in vivo. This is initially somewhat surprisinggiven the observation that VEGFR3 inhibition is inducing cell cycle
arrest and nondividing cells are felt to be resistant to DNA-damaging
chemotherapies such as cisplatin. However, chemosensitization was
greatest when cells were treated in sequence (VEGFR3 inhibition,
followed by cisplatin therapy), rather than concurrently. Thus,
VEGFR3 inhibition could induce cellular quiescence, and then when
cells resumed proliferation after withdrawal of VEGFR3 inhibitor,
chemotherapy then killed the cells as they entered the cell cycle. Killing
Figure 4. VEGFR3 inhibition with Maz51 chemosensitizes in vitro in a BRCA-dependent manner. (A) Absolute tumor cell number of
OVCAR8 and A2780 cells treated with Maz51 only, cisplatin chemotherapy only, cisplatin followed by Maz51, Maz51 and cisplatin
concurrently, or Maz51 followed by cisplatin is presented. (B) Normalized cell counts of PEO1 (BRCA2 mutant) and PEO4 cells (BRCA2
revertant) treated with the indicated agents are presented.
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Consistent with this, FACS evaluation of tumors treated with Maz51
and cisplatin demonstrated an increased percentage of CD133+ cells
but a reduced absolute number of CD133+ cells. CD133− cells had
both a decreased percentage, and 10-fold decrease and absolute number
of cells. This suggests that the CD133+ cells remained quiescent,
whereas the CD133− progenitor cells, which are normally highly
proliferative, are restricted by chemotherapy.
Our findings have important clinical implications. In both breast
and ovarian cancers, patients with BRCA mutations are known to
have a better clinical outcome [2,3]. This has been presumed to be
due to increased sensitivity to chemotherapy. Indeed, when BRCA
mutation carriers' tumors become resistant to cisplatin therapy, this
can be associated with reversion of one of the BRCA genes back to
wild type [4,40,48]. Our studies indicate that VEGFR3 inhibition
may represent a therapeutic means to downregulate BRCA expression
in BRCA wild-type tumors, thus making them mimic BRCA-
deficient tumors. Given a nearly 30% improvement in the overall
survival rate of patients with germline BRCA mutations over BRCA
wild-type patients with stage III/IV ovarian cancer, this simple
intervention could dramatically improve outcome. Furthermore, for
those patients who develop chemotherapy-resistant disease, it is
possible that VEGFR3 inhibition could reverse this phenomenon to
improve progression-free and overall survival.
Preclinical evidence supports VEGFR3 as a clinical target. VEGFR3
inhibitors have been found to both inhibit angiogenesis/lymphangiogenic
activities and reduce metastases [8,22,49]. Interestingly, a soluble version
of VEGFR3 has been identified [50]. Several studies have now usedsVEGFR3 as a “VEGF-C Trap” and reported significant reductions in
lymphangiogenesis and tumor metastases [27,51,52].
Clinical evidence also supports a potentially meaningful role for
VEGFR3 inhibitors. Recent studies suggested an ~5-month
progression-free survival for the VEGFR2/VEGFR3 inhibitor
pazopanib [53]. This is significantly better than the 8- to 10-week
progression-free survival advantage for the anti–VEGF-A antibody
bevacizumab [54,55]. We speculate that this could be due to the
significant anti–VEGFR3 inhibitory actions of pazopanib. In this
study, pazopanib was used only as a consolidation agent after
chemotherapy and not concurrent with chemotherapy. Our data
would suggest that use of pazopanib before or concurrent with
chemotherapy would dramatically enhance response rates. There is
currently an ongoing trial of another VEGFR3 inhibitor, BIBF-1120
(nintedanib), for the treatment of ovarian cancer. In this trial,
patients receive BIBF-1120 or placebo concurrent with standard
chemotherapy and as a consolidation agent. Our results would
suggest that this trial would show a significant benefit for the
experimental arm. If this or other trials with VEGFR3 inhibitors
show a significant clinical benefit compared to standard therapy
targeting the VEGF/VEGFR2 pathway, VEGFR3 expression on
cancer cells could be an important biomarker of patient response.
Our study also provides rationale for combining VEGFR3
inhibition with poly(ADP-ribose) polymerase (PARP) inhibitor
therapy. PARP inhibitor therapy has shown promise in BRCA
mutation carriers [56,57]. However, with the development of
platinum-resistant disease, nearly 50% of patient tumors demonstrate
gene reversions [4]. Use of VEGFR3 inhibitors in combination with
Figure 5. VEGFR3 inhibitor restricts tumor growth and increases chemosensitivity. (A and B) Tumor growth curves for OVCAR8 and
A2780 cell–derived tumors treated with single agent Maz51 are presented. (B) (i) Tumor growth curves for A2780 tumors treated with
cisplatin or Maz51 before and concurrent with cisplatin. Arrows indicate doses of cisplatin. Red bars indicate timing of daily Maz51
treatment. (ii) IHC analysis and quantification of Ki67 in cisplatin- and cisplatin +Maz51–treated A2780 tumors are presented. (C) (i) FACS
evaluation of CD133 and ALDH expression in cisplatin- and Maz51 + cisplatin–treated tumors and (ii) absolute numbers of CD133+ and
ALDH + cells in cisplatin- and Maz51 + cisplatin–treated tumors are presented.
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This hypothesis will be indirectly tested in an ongoing phase II
clinical trial comparing response rates for patients with ovarian cancer
treated with the PARP inhibitor olaparib and the pan VEGF receptor
inhibitor cediranib.
Our study is limited in that it was not performed with a
clinically available compound. Unlike the compounds discussed
above that target VEGFR1 to VEGFR3, Maz51 targets primarily
VEGFR3 in the concentrations used in this study. It remains to
be determined if VEGFR3 inhibition in the presence of
VEGFR1/2 inhibition will have similar activity. Similarly, our
study was limited to ovarian cancer. Further work will benecessary to see if a BRCA expression is also regulated by
VEGFR3 in breast cancer or other solid tumors.
In conclusion, we have found that tumor-associated myeloid cells
signal to cancer cells through VEGF-C interactions with VEGFR3.
VEGFR3 blockade results in down-regulation of BRCA genes, the
induction of cell cycle arrest, and chemosensitization. Given the
observation that BRCA mutant ovarian tumors have a much better
prognosis than BRCA wild-type tumors, our results imply that
VEGFR3, through down-regulation of BRCA, is a critical clinical
target for ovarian cancer. VEGFR3 inhibition could allow BRCA
wild-type patients to benefit from the improved clinical outcomes
observed for BRCA mutation carriers. In addition, VEGFR3
352 VEGFR3 Regulates BRCA1 and BRCA2 Expression Lim et al. Neoplasia Vol. 16, No. 4, 2014inhibition could allow chemosensitization for BRCA patients in
whom BRCA mutations have reverted to wild type.
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Figure W1.Maz51 does not induce apopotosis. PI/Annexin FACS analysis of control and Max51 treated OVCAR8 cells demonstrating no
increase in Annexin stain with Maz51 treatment.
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Supplemental Table 1. Information for Antibodies Used
Antibody Conjugation Source Clone
FACS
Anti-human CD133 APC Miltenyi Biotec 293C3
Anti-human VEGF R3 PE R&D system LGC03
Mouse IgG APC R&D Systems 20102
Mouse IgG PE R&D Systems 20102
IHC
Rat anti-mouse CD31 E-Bioscience 390
Rabbit polyclonal to LYVE1 Abcam polyclonal
Mouse anti-human Ki67 Abcam B126.1
Mouse anti-Human VEGF R3 Chemicon 9D9F9
Goat polyclonal antibody to VEGFC Santa Cruz 8 B1.3
Rat monoclonal to BRDU Abcam BU1/75 (ICR1)
Rabbit anti-rat biotinylated Vector Secondary Ab
Goat anti-rabbit biotinylated Vector Secondary Ab
Horse anti-mouse biotinylated Vector Secondary Ab
Rabbit anti-goat biotinylated Vector Secondary Ab
Goat anti-Rat IgG Alexa 488 Invitrogen Secondary Ab
Antibody Source Clone
Western blot
Mouse anti-human VEGF R3 Chemicon 9D9F9
Mouse anti-human p-VEGF R3 Calbiochem pc460
Goat polyclonal antibody to VEGFC Santa Cruz 8 B1.3
Rabbit mAb Erk1/2 Cell Signaling
Technology
D13.14.4E
Rabbit mAb P38 Cell Signaling
Technology
D3F9
Rabbit mAb JNK Cell Signaling
Technology
81E11
Rabbit polyclonal AKT Cell Signaling
Technology
polyclonal
Rabbit mAb stat3 Cell Signaling
Technology
D3Z2G
Rabbit mAb p-Erk1/2 Cell Signaling
Technology
137F5
Rabbit mAb p-P38 Cell Signaling
Technology
D13E1
Rabbit mAb p-JNK Cell Signaling
Technology
56G8
Rabbit polyclonal p- Cell Signaling
Technology
polyclonal
Rabbit polyclonal p-stat3 Cell Signaling
Technology
polyclonal
Mouse monoclonal β-Actin Santa Cruz AC-15
Horse anti-mouse IgG (H&L) antibody Cell Signaling
Technology
Secondary Ab






























353.e2 VEGFR3 Regulates BRCA1 and BRCA2 Expression Lim et al. Neoplasia Vol. 16, No. 4, 2014
